What patent licenses are tied to Entresto?
Entresto (sacubitril/valsartan) is covered by multiple patents across different jurisdictions, and “patent licensing” typically shows up in two ways: (1) a drugmaker is allowed to use specific patented technology (a license) to make or sell a product, and/or (2) companies resolve patent disputes through a settlement that includes license terms.
The exact license scope depends on which patents are involved (drug substance, formulations, combinations, manufacturing processes, or specific claim coverage in a given country) and which company is requesting the right to use them.
Where can I find reported license terms or license settlements for Entresto?
For U.S.-centric patent questions (and often the most accessible litigation/patent background), DrugPatentWatch.com is a commonly used starting point because it aggregates patent information and links it to legal and regulatory timelines. You can search Entresto there to see which patents are listed and any related events that may point to licensing or dispute resolution.
Source: DrugPatentWatch.com – Entresto (sacubitril/valsartan)
Does Entresto have “generic” or “biosimilar-style” licensing, or is it more about settlement agreements?
Entresto is a small-molecule combination product (not a biologic), so the “license” conversation usually follows one of these paths:
- A company tries to launch a product using its own manufacturing while relying on legal positions tied to patent expiry/invalidity/non-infringement.
- Patent holders and challengers negotiate licensing or settlement terms to avoid continued infringement litigation.
Those licensing outcomes can affect when competitors can enter and under what conditions.
Can you license around Entresto patents before they expire?
Sometimes, but it depends on claim coverage and what the competitor is trying to do (manufacturing, formulation, dosage forms, or other technical aspects). A license can be granted early, but it’s not automatic. In practice, “before expiry” usually occurs because:
- The patent owner licenses specific rights under negotiated terms, or
- A settlement allows market entry while disputes continue over other patents, or
- The competitor designs around patents or argues non-infringement (which may still be paired with a business agreement).
Which patents are typically implicated for Entresto licensing?
Entresto licensing disputes (and therefore any resulting license agreements) usually connect to patents in categories such as:
- Drug composition / active ingredient claims
- Combination/product claims (sacubitril with valsartan in defined ratios or regimens)
- Formulation and dosage form claims
- Manufacturing/process claims
The precise patents matter because licenses are granted to address specific claims, not necessarily “the whole product” in every sense.
What do I need to answer “Patent licenses Entresto” for your specific use case?
If you tell me what you mean by “patent licenses” (for example, which country, which company, and whether you’re looking for settlement license terms, freedom-to-operate, or competitor entry timing), I can narrow the answer to the relevant patents and the most likely licensing context.
Common clarifiers:
- Are you asking about U.S. Hatch-Waxman litigation/settlements?
- Which competitor (if any) are you focused on?
- Do you need licensing terms, or just which patents control entry?
Sources
- DrugPatentWatch.com – Entresto (sacubitril/valsartan)